Listen on the go
CORRECT!
Next question
touchENDOCRINOLOGY touchENDOCRINOLOGY

EUROPEAN ENDOCRINOLOGY VOLUME 13 – ISSUE 2 – AUTUMN 2017

View eJournal

We are delighted to welcome you to the Autumn edition of European Endocrinology, which includes a wide selection of diabetes content to coincide with the EASD 2017.

This edition includes two articles series for you to enjoy. The first explores the development of DPP-4 inhibitors, including vildagliptin, and how the treatment landscape has evolved since research began 25 years ago. The second series focuses on continuous glucose monitoring, and evaluates how it is been adopted within the UK. Further articles on diabetic macular oedema, diabetes pathophysiology and hyperthyroidism are also included for you to enjoy.

We hope you enjoy these articles, along with the multimedia content you will find accompanying many of the articles in this edition.

Thank you to all of our contributing authors. Our Editor-in-Chief Abd Tahrani would like to welcome all members of the endocrinology community to submit articles to our Spring 2018 edition. Visit our submission system if you have a paper to submit.

Foreward

General Endocrinology
Endo_22.png
General Endocrinology
Foreword – European Endocrinology, 2017;13(2):47

Welcome to the autumn edition of European Endocrinology. This issue features topical articles that have been selected for their evaluation of current practices, as well as case studies and research that directly affect endocrinologists and other practitioners involved in the care of patients with endocrine disorders. We begin with three articles that emphasise the importance […]

Letter from the Editor-in-Chief

General Endocrinology
Endo_11.png
General Endocrinology
Call for Submissions 2018
Abd Tahrani

Pathogenesis of Type 2 Diabetes

Diabetes
Endo_12.png
Diabetes
Beta-cell Insufficiency
Sanjay Kalra, Yashdeep Gupta

Type 2 Diabetes

Diabetes
Endo_7.png
Diabetes
The Vildagliptin Experience – 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration
James E Foley, Bo Ahrén

Diabetes
Endo_21.png
Diabetes
Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin – Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes
William David Strain, Päivi M Paldánius

Diabetes
Endo_22.png
Diabetes
Clinical Safety and Tolerability of Vildagliptin – Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance
Chantal Mathieu, Plamen Kozlovski, Päivi M Paldánius

Continuous Glucose Monitoring

Diabetes
Endo_22.png
Diabetes
Continuous Glucose Monitoring Adoption in the United Kingdom – An Economic and Policy Perspective
Nick Oliver

Diabetes
Endo_21.png
Diabetes
Is Continuous Glucose Monitoring Underappreciated in the UK?
Christopher G Parkin, Melissa Holloway, Jeffrey Truesdell

Diabetes
Endo_10.png
Diabetes
An Economic Evaluation of Continuous Glucose Monitoring for People with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia within North West London Clinical Commissioning Groups in England
Shraddha Chaugule, Nick Oliver, Brigitte Klinkenbijl

Cardiovascular Risk

Cardiovascular Risk, Diabetes
Endo_8.png
Cardiovascular Risk, Diabetes
Antihyperglycemic Medications and Cardiovascular Risk Reduction
Sarah L Anderson, Joel C Marrs

Diabetic Macular Edema

Diabetes
Endo_16.png
Diabetes
Ranibizumab in Diabetic Macular Oedema – A Benefit–risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment
Focke Ziemssen, Alan Cruess, Cornelia Dunger-Baldauf

Hyperthyroidism

Diabetes, Thyroid Disorders
Endo_20.png
Diabetes, Thyroid Disorders
Type 2 Diabetes Decompensation as the Clinical Presentation of Thyroid Storm – Cause or Consequence?
Ana Margarida Monteiro, Cláudia Matta-Coelho, Vera Fernandes

Trending

New Trends in Treating Cushing’s Disease
Pituitary Disorders
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72